Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604927 | 1.00 | MAPT (0.61) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL2604953 | 0.89 | BACE1 (0.61) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL2604931 | 0.88 | CYP1A2 (0.61) | MAPTHPGDKDM4ECYP1A2CYP3A4 | |
| SCHEMBL6499271 | 0.85 | POLB (0.56) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL29227143 | 0.82 | CYP1A1 (0.47) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL29227146 | 0.82 | CYP1A1 (0.47) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6496200 | 0.82 | MEN1 (0.55) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL2604951 | 0.82 | CYP1A2 (0.55) | MAPTHPGDKDM4ECYP1A2CYP3A4 | |
| SCHEMBL6495751 | 0.82 | CYP1A2 (0.49) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6491093 | 0.81 | MEN1 (0.54) | MAPTLMNAHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | claimed |
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY | 2003-04-17 | — | — | US | disclosed |
| EP-1272469-A1 | NAPHTHALENE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1138328-A1 | Naphthalene derivatives as CNS drugs | ELI LILLY AND COMPANY LIMITED (GB) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001072709-A1 | NAPHTALENE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | CHRNA6, ATP6V1B2, GRM6 | MAPT 2452/4885LMNA 3238/4885HPGD 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.